Ex vivo functional experiments showed that, in vivo CTEP chronic treatment reduced the excessive glutamate release evoked by high KCl or mGlu1/5 receptor activation, supporting the main role played by excessive glutamate neurotransmission in ALS and the involvement of mGlu5 receptors in this phenomenon. The gene discussed is GRM1; the disease is amyotrophic lateral sclerosis.